OrthoPediatrics (KIDS) FY Conference August 13, 2025 11:00 AM ET Speaker0Good morning, everyone, and thank you for joining us at this year's Canaccord Genuity Global Growth Conference. My name is Caitlin Cronin, and I'm on the medical device team here at Canaccord Genuity. I'm joined today by OrthoPediatrics, a medical device company dedicated to developing orthopedic solutions exclusively for the pediatric population. And with me today are Dave Bailey, CEO, and Fred Hite, CFO. And before we begin, I want t ...

Summary of IAC FY Conference Call - August 13, 2025 Company Overview - **Company**: IAC (InterActiveCorp) - **Key Businesses**: - People Inc (formerly Dotdash Meredith) - Care.com - Vivien Health (healthcare staffing) - The Daily Beast - Search business - **Financial Position**: $900 million in cash at the parent level with no debt at the parent level, although there is debt at People Inc which was refinanced attractively in June [10][11][12] Rebranding and Digital Transition - **Rebranding**: Transition from Dotdash Meredith to People Inc aimed at simplifying the brand for better recognition and marketability [5][6][13][15] - **Digital Focus**: The company is transitioning from print to digital, with a significant reduction in print publications from 12-13 to 7 over three years. The print business is maintained for branding and cash flow purposes [18][19][20] - **Digital Revenue**: 64% of the company's digital revenue comes from owned and operated (O&O) websites, with a focus on diversifying traffic sources beyond Google [25][28] Growth and Future Opportunities - **Long-term Goals**: Targeting 10% digital growth, with potential upside through new brands and leveraging consumer data [31][33] - **Decipher Tool**: An ad targeting tool that utilizes first-party data to enhance advertising effectiveness, potentially increasing the total addressable market (TAM) for ad sales [33][82] - **Care.com Growth**: Aiming for 10-20% growth in the consumer segment by improving product offerings and marketing strategies [94][97] Advertising Market Insights - **Market Conditions**: The advertising market is described as "good, not great," with sector-specific performance. Health and pharma are solid, while CPG and food and beverage sectors are facing challenges [68][71] - **Programmatic Advertising**: Programmatic revenue accounts for about 25-30% of total digital revenue, with recent improvements noted in pricing and demand [75][77] Strategic Partnerships and Licensing - **LLM Licensing**: The company is exploring licensing deals with LLM (Large Language Model) providers, emphasizing the need for high-quality content and potential economic arrangements [39][41] - **Cloudflare Partnership**: A partnership aimed at blocking LLM crawlers, except for OpenAI, has led to increased discussions with other LLM providers about accessing content [40] Financial Management and Shareholder Value - **Share Repurchases**: The company has been cautious with share buybacks, having repurchased $200 million worth of stock earlier in the year, while also considering M&A opportunities [58][59] - **Corporate Overhead**: Targeting a reduction in corporate overhead expenses, aiming for a run rate of $80-90 million by year-end [63][65] Key Business Segments - **Vivien Health**: Positioned as a strategic asset in healthcare staffing with a marketplace model connecting nurses and healthcare systems, currently generating mid-eight figures in revenue [99][100] - **Care.com**: Focused on stabilizing and growing the consumer segment after a decline in subscribers, with a new CEO implementing product improvements [96][97] Conclusion - The company is optimistic about its future growth prospects, leveraging its strong brand portfolio and digital capabilities to navigate the evolving media landscape [36][56]

Summary of PTC FY Conference Call - August 13, 2025 Company Overview - **Company**: PTC (PTC) - **Event**: Oppenheimer Virtual Tech Conference - **Date**: August 13, 2025 Key Points Industry and Market Environment - The macro environment remains challenging but has not materially worsened, leading to a stable outlook for PTC [10][12][13] - There was initial caution among customers at the start of the quarter due to uncertainty surrounding "Liberation Day" [5][6] - PTC's revised guidance reflects a more stable outlook, with net new Annual Recurring Revenue (ARR) coming in at the high end of expectations [8][9] Financial Performance - PTC achieved near the high end of its guidance range for net new ARR, indicating alleviation of worst-case fears [8] - The company is on track to meet its $1 billion free cash flow target for the next fiscal year, despite currency and tax fluctuations [52][58] Go-to-Market Strategy - PTC has made significant changes to its go-to-market strategy, focusing on core verticals and aligning sales, marketing, and customer success teams [17][21] - The restructuring involved account reshuffling and hiring to optimize territory coverage [20][21] - Ongoing efforts include refining messaging for verticals and enhancing pipeline management [23][24] Product Development and AI Integration - PTC views Product Lifecycle Management (PLM) as a strategic imperative for customers, emphasizing the need for faster and more sophisticated product development [34] - The company is in the early stages of integrating AI into its products, with plans for broader AI capabilities to be rolled out in the near future [47][48] - Monetization strategies for AI are still being developed, with current offerings priced on a per-seat basis [50] Customer Engagement and SaaS Transition - There is growing customer interest in SaaS as a delivery model, although migration involves significant organizational change management [40][41] - PTC aims to balance the needs of existing on-premise customers while facilitating the transition to SaaS [42] Future Outlook - PTC is evaluating its growth profile in light of the current macro environment, with a focus on driving net new ARR growth through strategic initiatives [32][33] - The company plans to provide guidance for fiscal 2026 during the Q4 results announcement [59] Capital Allocation - PTC aims to operate in a net debt position and prioritize returning excess cash to shareholders through share repurchases [61] Additional Insights - The company is addressing elevated churn related to specific product lines and customer situations, with some contracts expected to return by the end of the year [35][36] - PTC is actively managing foreign exchange impacts and tax changes to mitigate financial headwinds [54][56] This summary encapsulates the key discussions and insights from the PTC conference call, highlighting the company's strategic direction, financial performance, and market positioning.

Upland Software (UPLD) FY Conference Summary Company Overview - Upland Software has undergone a significant business transformation over the last eighteen months, focusing on divesting underperforming assets and concentrating on markets with strong competitive advantages, high margins, and growth rates [4][20] - The company has built an offshore development center in India to enhance product innovation and has AI-enabled its product portfolio [4][6] Financial Performance - Upland has repaid $242 million of debt since the beginning of the previous year, reducing net debt leverage to 3.9 times, with a target of 3.7 times by year-end [5] - Adjusted EBITDA margins have improved from 20% last year to 27% this year, with expectations to exceed 30% in the back half of the year [6][24] - The company reported approximately $200 million in annual total core revenue, growing at over 2.5% in the latter half of the year [7][19] - 93% of Upland's revenue is recurring, with a net dollar retention rate of 99% [9][15] Market Position and Growth - Upland operates in an $11 billion market that is growing at 15% annually [7][16] - The company aims for long-term organic growth in the mid to upper single digits [17][31] - Upland's products are highly rated and serve a diverse range of industries, including technology, financial services, healthcare, and manufacturing [16] Product and Customer Insights - Upland's AI-powered knowledge and content management software provides real ROI for enterprise customers [6][11] - Notable customer success stories include significant cost savings achieved through Upland's products, such as a global payroll processor saving $4 million annually and a top-tier US bank saving $6 million [12][13] - The average annual recurring revenue (ARR) for Upland's 1,100 enterprise accounts is approximately $137,000, representing nearly 90% of recurring revenue [15] Strategic Focus - The company is shifting from an acquisition-driven growth model to a focus on organic growth and product improvement [30][31] - Upland is enhancing its sales strategy by moving back to a field sales model, hiring salespeople with niche market experience [35][36] - Marketing efforts have been centralized while also incorporating digital marketing strategies to improve lead generation [38] Debt Refinancing and Future Outlook - Upland has successfully refinanced its debt, extending maturity by six years and adding a $30 million undrawn revolver for liquidity [5][41] - The management team is focused on maintaining a simple, product-driven business model while continuing to pay down debt [31][32] - The company anticipates that reported numbers will improve as divestitures and sunset assets are behind them, leading to increased visibility and interest from investors [45]

KORU Medical Systems (KRMD) FY Conference August 13, 2025 10:30 AM ET Speaker0Alright. Good morning, everyone, and welcome to this year's Canaccord Genuity Global Growth Conference. My name is Caitlin Cronin, and I'm on the medical device team here at Canaccord Genuity. Coru Medical is joining us today, and they're a medical device company focused on innovative portable solutions for the drug delivery market. We're very pleased to be joined today by Linda Tharby, President and CEO, as well as Tom Adams, CFO ...

Summary of Aldeyra Therapeutics (ALDX) FY Conference Call Company Overview - **Company**: Aldeyra Therapeutics (ALDX) - **Focus**: Immunology with an emphasis on ophthalmology, particularly in the treatment of dry eye disease and other ocular conditions [3][4] Pipeline and Product Development - **Lead Product**: Reproxalap, a topical eye drop candidate for dry eye disease, is a RASP modulator targeting reactive aldehyde species [5][6][7] - **NDA Resubmission**: The company resubmitted the New Drug Application (NDA) for reproxalap, with a PDUFA date set for December 16, 2025. The last FDA feedback indicated the need for an additional symptom trial [5][8][10] - **Clinical Trials**: The company has conducted trials in dry eye chambers to demonstrate the drug's efficacy within minutes, addressing a significant gap in the current treatment landscape where existing therapies do not provide rapid relief [12][13][36] Market Opportunity - **Dry Eye Disease**: The prevalence of dry eye disease is expected to increase due to aging populations and increased screen time. Current treatments are limited and often ineffective for moderate to severe cases [11][12][14] - **Differentiation**: Reproxalap aims to be the first drug to address both symptoms and signs of dry eye disease, including redness and discomfort, which is not currently available in the market [16][46] Strategic Partnerships - **Collaboration with AbbVie**: AbbVie holds an option for reproxalap, which includes potential development for allergic conjunctivitis. The partnership is seen as advantageous given AbbVie's experience in the dry eye market [24][26][28] Additional Pipeline Products - **ADX-2191**: An intravitreal formulation of methotrexate for ocular lymphoma and retinitis pigmentosa. The company is preparing for pivotal trials in retinitis pigmentosa, a condition affecting peripheral vision [52][58] - **ADX-246**: A product targeting dry age-related macular degeneration (AMD), focusing on improving low-light vision and addressing early stages of the disease [66][70] Future Directions - **Focus on Mild to Moderate Diseases**: Aldeyra aims to address mild to moderate forms of diseases, which are often overlooked in the current treatment landscape. This approach is expected to meet the needs of a larger patient population [72][73] - **RASP Modulation Platform**: The RASP platform allows for the modulation of multiple proteins simultaneously, indicating a potential shift in treatment paradigms towards more comprehensive therapies [74] Key Takeaways - Aldeyra is positioned to potentially revolutionize the treatment of dry eye disease with reproxalap, focusing on rapid relief and addressing both symptoms and signs [16][46] - The collaboration with AbbVie enhances the company's market position and development capabilities [24][26] - The pipeline extends beyond dry eye disease, with promising developments in ocular lymphoma and retinitis pigmentosa, indicating a broad therapeutic focus [52][58]

Summary of Artivion (AORT) FY Conference Call - August 13, 2025 Company Overview - **Company**: Artivion (AORT) - **Focus Areas**: Aortic valves for patients aged 65 and older, aneurysms, and dissections, particularly in the aortic arch [2][69] Core Business Model - **Business Model**: Highly differentiated, profitable, and growing base business with a focus on aortic valves and stents [3][70] - **Revenue Growth**: Expected to grow revenue in double digits on the top line and twice as fast on the bottom line for the foreseeable future [4][71] Financial Performance - **On X Valves Growth**: Grew 24% in the quarter; historically, it has grown at 13% over the last decade [5][72] - **Clinical Evidence**: Unique position due to clinical evidence supporting lower INR (less blood thinner) usage, leading to a significant market share increase [5][72] - **Market Opportunity**: Targeting a $100 million tissue valve market opportunity based on recent clinical findings [7][74] - **Stent Business Growth**: Stent business grew 22% in the quarter, with a strong pipeline for future growth [8][75] Product Pipeline - **Pipeline Overview**: Five PMAs (Premarket Approvals) in the pipeline with a total market opportunity of approximately $1 billion [18][86] - **Upcoming Products**: - **AMDS**: Stent for acute type A dissection, showing significant mortality reduction in trials [12][79] - **Nexus**: Total catheter delivery system for aortic arch replacement, expected FDA approval in 2026 [14][82] - **SIVO**: Next-generation frozen elephant trunk device, trial approved and expected to start enrollment soon [16][83] Financial Guidance - **2025 Revenue Guidance**: Initially projected at 10% to 14%, now narrowed to 12% to 14% growth [17][84] - **EBITDA Guidance**: Adjusted EBITDA expected to be between $86 million and $91 million, with a positive cash flow outlook [18][85] Competitive Landscape - **Competition**: Limited direct competition in the AMDS space; standard of care is outdated [29][96] - **Market Position**: Approximately 60% market share in mechanical valves in the U.S. and 15% in the tissue valve market [64][112] Key Takeaways - **Strong Leadership**: Experienced leadership team contributing to the company's growth and innovation [2][70] - **Positive Physician Feedback**: Excellent feedback on AMDS technology, highlighting ease of use and significant clinical benefits [31][100] - **Future Focus**: Continued emphasis on training and cross-selling to expand market presence and drive new account creation [47][113] Additional Insights - **Deleveraging Strategy**: Rapid deleveraging of the balance sheet, with a current leverage ratio of around 2.2 [17][84] - **Cash Flow Utilization**: Future cash flow expected to be used for debt reduction and potential acquisition of Endospan [24][91]

Summary of General Motors Conference Call Company Overview - **Company**: General Motors (GM) - **Industry**: Automotive Key Points and Arguments Financial Performance and Expectations - GM's performance in July was generally in line with expectations, with a slight uptick in industry incentive levels while GM's incentives were down [2][3] - The company anticipates a significant impact from tariffs in 2025, estimating a gross headwind of $4 billion to $5 billion, but expects to generate $7.5 billion to $10 billion in free cash flow [7][16] - GM is committed to achieving an 8% to 10% margin level in North America and is making progress towards this goal [6][14] Tariff and Trade Deal Implications - The administration's trade deals, particularly with Korea, could lead to hundreds of millions in savings on tariffs by 2025 [4][5] - GM is focused on a three-pillar strategy to offset tariff impacts: go-to-market initiatives, manufacturing footprint changes, and fixed cost reductions [10][11] - The company has seen a reduction in the cost of tariffs as a percentage of retail price, now tracking in the mid-single digits [9] Electric Vehicle (EV) Market Dynamics - There is a pull ahead in EV sales due to the impending elimination of the $7,500 consumer tax credit [3] - The regulatory landscape for EVs is complex, with potential headwinds from the expiration of tax credits and penalties for noncompliance with greenhouse gas regulations [34][36] - GM believes that the elimination of GHG penalties could lead to a more rational market for EVs, reducing irrational pricing behavior [39] Manufacturing and Capacity Investments - GM announced a $4 billion investment to increase U.S. vehicle production capacity by nearly 2 million units, which includes full-size SUV production [13][28] - The company is focused on maintaining discipline in production and avoiding overbuilding, which could lead to inventory issues in future economic cycles [31][32] Market Share and Competitive Position - GM has gained market share in China, with a 20% year-over-year sales increase driven by battery electric and plug-in hybrid vehicles [49][50] - The company is confident in its product portfolio and expects to outperform the industry by 1% to 2% over the next couple of years [59][60] Software and Services Revenue - GM has a deferred revenue balance of $4 billion, which is expected to grow significantly as subscriptions for services like Super Cruise are recognized [64][65] - The company is focused on improving margins through software services, which are expected to contribute positively to overall profitability [63] Future Outlook - GM is optimistic about its ability to navigate the current challenges and is preparing for a budget process for 2026 amidst ongoing trade negotiations [20][27] - The company is committed to evolving its autonomous vehicle technology and improving personal autonomy features in its vehicles [70][72] Additional Important Insights - GM's approach to managing unforeseen challenges, such as the pandemic and semiconductor shortages, reflects a more resilient and flexible operational strategy compared to historical practices [7][8] - The company emphasizes the importance of maintaining a strong vehicle portfolio and competitive pricing strategies to drive future growth [61][62]

Summary of Conference Call Company Overview - The conference call involved HIMS, a healthcare technology company focused on improving consumer healthcare experiences through technology and personalized solutions [3][4][5]. Core Industry Insights - The healthcare industry is evolving with technology aimed at reducing friction in consumer experiences, similar to advancements seen in other sectors like transportation (Uber) and entertainment (Netflix) [4]. - HIMS aims to democratize healthcare services, making them accessible to a broader consumer base while enhancing capabilities such as lab diagnostics and personalized treatments [5][10]. Strategic Priorities - HIMS' strategy focuses on leveraging technology to enhance consumer healthcare experiences, emphasizing awareness, access, and affordability [3]. - The company has expanded its platform capabilities significantly, reducing the time for patients to connect with medical experts from weeks to often less than 24 hours [5]. Personalization and Investments - Recent acquisitions and capital expenditures are aimed at enhancing personalized healthcare solutions, driven by consumer feedback on treatment adherence and side effects [6][7]. - HIMS has over 2.4 million subscribers, providing a substantial data set to improve personalized healthcare offerings [8]. AI Integration - HIMS is utilizing AI to streamline provider experiences and enhance the customer journey, including diagnostic tools that optimize treatment plans based on consumer attributes [11][12]. - Future developments may include AI-driven nutritional coaching and mental health support [14]. Market Opportunities - HIMS plans to launch new offerings in low testosterone and menopausal support, identifying these markets as large and underserved [15][16]. - The company sees potential in addressing conditions that consumers may not be aware they have, thus expanding the market for treatments [16]. Weight Loss Segment - The weight loss segment remains a key focus, with over 100 million individuals in the U.S. facing weight-related challenges [21]. - HIMS emphasizes the importance of provider interaction and holistic treatment approaches beyond medication [23][24]. Regulatory Considerations - Concerns regarding regulatory risks associated with compounding medications were addressed, with HIMS asserting compliance with existing laws and transparency in consumer data [27][30]. International Expansion - HIMS is expanding into European markets, leveraging insights gained from its UK operations and the recent acquisition of Zava [35][36]. - The company plans to launch in Canada, anticipating the availability of generic semaglutide, which aligns with its strategy to address obesity challenges [40][41]. Financial Performance and Growth Drivers - Despite decelerating growth in core segments, HIMS reports strong performance in various specialties, with growth rates exceeding 55% in several areas [43][44]. - The company is focused on long-term strategies to enhance customer retention and expand its product offerings, particularly in sexual health [44][46]. Conclusion - HIMS is positioned to capitalize on significant market opportunities through technology-driven personalization, strategic acquisitions, and a focus on consumer needs in the evolving healthcare landscape [39][46].

Summary of EyePoint Pharmaceuticals (EYPT) FY Conference - August 13, 2025 Company Overview - **Company**: EyePoint Pharmaceuticals - **Focus**: Development of sustained-release therapies for ocular diseases, specifically targeting wet age-related macular degeneration (AMD) with their drug Duravu Key Points and Arguments Clinical Trials and Drug Development - **Phase Three Trials**: Both Lugano and Lucia trials for Duravu have completed enrollment, including treatment naive and treatment experienced patients, which is expected to positively impact future data readouts [3][4][5] - **Patient Population**: The trials have a 75% treatment naive to 25% previously treated patient ratio, which is considered advantageous for FDA evaluation [8][10][12] - **Safety Profile**: No safety signals were observed in previous trials, and the inclusion of naive patients is not expected to alter safety outcomes [6][42] - **Supplemental Injections**: The criteria for supplemental injections have been simplified based on phase two findings, aiming to reduce the supplemental rate in pivotal trials [13][15][17] Drug Technology - **DuraCert e Technology**: The new bioerodible DuraCert e technology differs from previous DuraCer technology by eliminating the polyamide shell, which is expected to enhance safety and efficacy [20][22][26] - **Drug Composition**: The inserts are now 94% drug and 6% matrix, designed to fully bioerode without leaving harmful residues [27][28][32] Market Expectations and Competitive Landscape - **Regulatory Pathway**: Vorolanib, the active ingredient in Duravu, has been approved in China for kidney cancer but is a new drug entity in the U.S., providing potential advantages in patent protection [44][46] - **Real-World Use**: Duravu is expected to be integrated into existing treatment protocols, potentially allowing for longer intervals between injections compared to current therapies like Eylea and Lucentis [47][49][52] - **Payer Receptiveness**: Payers have shown receptiveness to the idea of a sustained release therapy that reduces treatment burden, which is a significant factor in market adoption [55][56] Financial and Operational Readiness - **Manufacturing Capacity**: EyePoint has established a new manufacturing facility capable of producing hundreds of thousands of inserts annually, with potential expansion to a million inserts [57][59] - **Cash Runway**: The company has sufficient cash to complete pivotal trials and prepare for regulatory approval, with optimism about raising additional funds for commercialization [63][64] Future Outlook - **Data Expectations**: Top-line data from the Lugano trial is expected in mid-2026, with hopes of demonstrating noninferiority or even superiority to Eylea [36][38][62] - **Market Positioning**: The company is optimistic about the potential for rapid uptake of Duravu in the market, especially if pivotal trial results are positive [54][65] Additional Important Information - **Patient Engagement**: Rapid enrollment in trials indicates strong enthusiasm from both doctors and patients for the drug [36] - **Clinical Evidence**: Previous studies suggest that Duravu may provide better visual acuity outcomes compared to existing treatments [41][62]